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Introduction
Tatton-Brown-Rahman syndrome (TBRS; OMIM 615879), 
also known as the DNMT3A-overgrowth syndrome, is an over-
growth intellectual disability (OGID) syndrome first described in 
2014 with a report of 13 individuals with de novo heterozygous 
DNMT3A variants1,2. Subsequently, a further 22 individuals 
with TBRS have been reported3–9.
In this report we have undertaken a detailed clinical evaluation 
of 55 individuals with de novo DNMT3A variants, including the 
13 individuals we first reported in 2014. We have expanded and 
clarified the TBRS phenotype, delineating major and frequent 
clinical associations, which has informed our management of 
individuals with this new OGID syndrome.
Methods
The study was approved by the London Multicentre Research 
Ethics Committee (MREC MREC/01/2/44). Patients were identi-
fied through Clinical Genetics Services worldwide and written 
informed consent was obtained from all participating individuals 
and/or parents. Photographs, with accompanying written informed 
consent to publish, were requested from all participants and 
received from the families of 41 individuals. Detailed phenotype 
data were collected through a standardized clinical proforma, a 
DNMT3A specific clinical proforma and clinical review by one of 
the authors. Growth parameter standard deviations were calculated 
with reference to UK90 growth data10.
The degree of intellectual disability was defined in relation to 
educational support as a child and living impairment as an adult:
- an individual with a mild intellectual disability typically 
had delayed milestones but would attend a mainstream 
school with some support and live independently, with 
support, as an adult;
- an individual with a moderate intellectual disability typi-
cally required high level support in a mainstream school 
or special educational needs schooling and would live 
with support as an adult;
- an individual with a severe intellectual disability typically 
required special educational needs schooling, had limited 
speech, and would not live independently as an adult.
55 individuals were included with a range of de novo 
heterozygous DNMT3A variants: missense variants (36 individu-
als with 30 different variants); stop gain variants (six individuals); 
frameshift variants (six individuals); whole gene deletions (four 
individuals including identical twins (COG1961 and COG2006)); 
in-frame deletions (two individuals) and a splice site variant (one 
individual, Figure 1, Table 1). Computational tools predicted 
all 30 missense variants to be deleterious (Mutation Taster2 and 
SIFT (version 6.2.1), Supplementary Table 1) and the splice site 
variant was predicted to disrupt normal splicing. Importantly, 
some of the variants are common in the general population due to 
Figure 1. DNMT3A and the positions and types of variants with protein truncating variants shown below the protein (black and red 
lollipops) and missense variants and inframe deletions (yellow and blue lollipops) shown above the protein. Whole gene deletions and 
the splice site variant are not shown on this figure. The three DNMT3A domains are shaded in grey: the proline-tryptophan-tryptophan-proline 
(PWWP) domain, the ATRX-Dnmt3-Dnmt3L (ADD) domain and the Methyltransferase (MTase) domain.
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age-related clonal haematopoiesis, limiting the utility of databases 
such as gnomAD in DNMT3A variant pathogenicity stratification 
(Supplementary Table 1)11,12.
Results
All 55 individuals had an intellectual disability: 18% had a 
mild intellectual disability (10/55); 65% had a moderate intel-
lectual disability (36/55) and 16% had a severe intellectual 
disability (9/55) (Table 1, Figure 2). Behavioural/psychiatric issues 
were reported in 51% (28/55) individuals and included combi-
nations of autistic spectrum disorder (20 individuals); anxiety 
(three individuals); neurodevelopmental regression (four individu-
als two of whom regressed in teenage years); psychosis/schizo-
phrenia (three individuals); aggressive outbursts (two individuals), 
and bipolar disorder (two individuals) (Table 1).
Postnatal overgrowth (defined as height and/or head circumfer-
ence at least two standard deviations above the mean (≥2SD)2,13, 
was reported in 83% (44/53) individuals. Obesity, with a weight 
≥2SD, was reported in 67% (34/51). The range of individual 
postnatal heights, head circumferences and weights is shown 
in Table 1 and Figure 3. The mean birth weight was 1.3SD with 
a range from -1.1 to 4.0 SD. We had limited data for birth head 
circumference and birth length, but their mean was 2.3SD and 
1.6SD, respectively.
There were some shared, but subtle, facial characteristics often 
only becoming apparent in early adolescence (Figure 4a and b). 
These included low-set, horizontal thick eyebrows; narrow palpe-
bral fissures; coarse features and a round face. The two upper 
central incisors were also frequently enlarged and prominent.
Additional clinical features reported in greater than 20% (≥ 11) 
individuals included: joint hypermobility (74%, 37/50); hypo-
tonia (54%, 28/52); kyphoscoliosis (33%, 18/55) and afebrile 
seizures (22%, 12/55) (Table 1). In addition, short, widely spaced 
toes were frequently mentioned, but the overall frequency is 
unclear as we did not specifically ask about feet/toes on the 
clinical proforma (Figure 4c).
Clinical features reported in at least two but fewer than 20% 
individuals included cryptorchidism (six individuals); ventricu-
lomegaly (four individuals) and Chiari malformation (three indi-
viduals). In addition, a range of cardiac anomalies (including 
atrial septal defect, mitral/tricuspid valve incompetence, patent 
ductus arteriosus, aortic root enlargement and atrio-ventricular 
re-entry tachycardia) were reported in nine individuals. However, 
of note, two individuals with cardiac anomalies (patent ductus 
arteriosus, COG1961 and COG2006) were identical twins with 
DNMT3A whole gene deletions encompassing >40 genes. The 
patent ductus arteriosus in these individuals may, therefore, be 
attributable to twinning, alternative genes in the deleted region 
or the combined effect of a number of deleted genes.
Acute myeloid leukaemia (AML), AML-FAB (French-American-
British classification) type M4, was diagnosed in one individual 
Figure 2. Graph showing the range of intellectual disability in 
TBRS.
at the age of 12 years (COG2004). This individual had a de 
novo heterozygous c.2204A>C p.(Tyr735Ser) DNMT3A variant, 
identified in DNA obtained seven years prior to the diagnosis of 
AML.
Full clinical details from the 55 individuals are provided in 
Table 1.
Discussion
We have evaluated clinical data from 55 individuals with 
de novo constitutive DNMT3A variants to define the pheno-
type of TBRS. An intellectual disability (most frequently in the 
moderate range) and overgrowth (defined as height and/or head 
circumference ≥2SD above the mean) were reported in ≥80% of 
individuals and have been designated major clinical associations. 
Frequent clinical associations, reported in 20–80% of individu-
als with constitutive DNMT3A variants, included joint hypermo-
bility, obesity, hypotonia, behavioural/psychiatric issues (most 
frequently autistic spectrum disorder), kyphoscoliosis and afe-
brile seizures. In addition, many individuals had a characteris-
tic facial appearance although this may only be recognizable in 
adolescence.
TBRS overlaps clinically with other OGID syndromes includ-
ing Sotos syndrome (OMIM 117550), Weaver syndrome 
(OMIM 277590), Malan syndrome (OMIM 614753) and the 
OGID syndrome due to CHD8 gene variants2. However, TBRS is 
more frequently associated with increased weight than the other 
OGID syndromes and may be distinguishable through recognition 
of the associated facial features, and absence of the facial gestalt 
of other OGID syndromes.
Somatic DNMT3A variants are known to drive the development 
of adult AML and myelodysplastic syndrome and over half of the 
DNMT3A somatic variants target a single residue, the p.Arg882 
residue14–17. AML, diagnosed in childhood, has now been identi-
fied in two individuals with (likely) constitutive DNMT3A variants 
from a total of 77 (1/55 individuals in the current study and 1/22 
previously reported individuals)7. One of these individuals had a 
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Figure 3. Growth profile in individuals with TBRS a) height, b) head circumference and c) weight. The blue line represents the mean.
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Figure 4. a) The facial appearance of children and adults with TBRS; b) the evolving facial appearance in four individuals with TBRS; and 
c) the characteristic short, widely spaced toes seen in TBRS.
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de novo c.2644CT p.(Arg882Cys) DNMT3A variant and devel-
oped AML at 15 years of age7. The variant was present in genomic 
DNA extracted from the patient’s remission blood sample and skin 
fibroblasts. The second individual had a c.2204A>C p.(Tyr735Ser) 
DNMT3A variant identified in DNA obtained at 5 years of age and 
developed AML at the age of 12 years. Whilst these data indi-
cate that AML may be a rare association of TBRS, currently the 
numbers of individuals reported with TBRS and AML are too few 
to either accurately quantify the risk of AML in TBRS or deter-
mine whether this risk is influenced by the underlying DNMT3A 
genotype. Further studies are required to address this.
The majority of individuals with TBRS are healthy and do not 
require intensive clinical follow up. However, our practice is to 
inform families and paediatricians of the possible TBRS com-
plications of behavioural/psychiatric issues, kyphoscoliosis and 
afebrile seizures to introduce a low threshold for their investiga-
tion and/or management. In addition, we undertake a baseline 
echocardiogram at initial diagnosis to investigate cardiac anoma-
lies detectable on ultrasound scan and frequently refer patients to 
physiotherapy to evaluate the degree of hypotonia and/or joint 
hypermobility and to determine whether targeted exercises may 
be beneficial. Finally, in the absence of evidence-based surveil-
lance protocols for haematological malignancies, we advise 
clinical vigilance for symptoms possibly related to a haema-
tological malignancy such as easy bruising, recurrent bleed-
ing from gums or nosebleeds, persistent tiredness and recurrent 
infections.
Ethics and consent
The study was approved by the London Multicentre Research 
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